Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

Changes in Amino Acid Absorption After Adding a Probiotic to an Acute Protein Feeding

NCT06701604 · tracked via the Priya Life Science USA tracker
Phase
Not applicable
Started
2024-12-02
Last updated
2024-11-22

Condition(s) studied

Amino Acid AbsorptionProbiotic

Investigational drug(s) / intervention(s)

Single Strain Probiotic + Milk ProteinPlacebo + Milk Protein

Single Strain Probiotic + Milk Protein: • Both conditions matched flavor, color, and serving size

Placebo + Milk Protein: • Both conditions matched flavor, color, and serving size

Study summary

The purpose of this study is to examine the rate and concentration of amino acid absorption after a three-week pattern of milk protein supplementation with and without the addition of a single strain probiotic.

Eligibility

Sex
ALL
Min age
18 Years
Max age
35 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Participants will be male or female between the ages of 18-35 years; * Participants have not been consuming any nutritional supplements for the preceding 6-week period; * Participants have not been consuming any ergogenic aids for the preceding 6-week period; * Participant has provided written and dated informed consent to participate in the study; * Participant is willing and able to comply with the protocol; * Participant is apparently healthy and free from disease, as determined by a health history questionnaire; Exclusion Criteria: * Participant is allergic to any ingredient in the nutritional supplement or placebo; * Participant is not pregnant or trying to become pregnant, nor breast feeding; * Participant reports any unusual adverse events associated with this study that in consultation with the study investigators or their doctor recommends removal from the study; * Participant currently ingests nicotine or has quit within the last 6 months;

Primary outcome measure(s)

  • Rate of amino acid absorption — Day 0, Day 22, Day 65
    To determine if the addition of a probiotic to milk protein ingestion changes the rate (in minutes) to which amino acids are absorbed into our bloodstream.
  • Concentration of amino acid absorption — Day 0, Day 22, Day 65
    To determine if the addition of a probiotic to milk protein ingestion changes the extent (concentration in millimoles/Liter) to which amino acids are absorbed into our bloodstream.

Trial sites (1)

FacilityCityRegionStatus
The University of Mary Hardin-Baylor Belton Texas
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06701604 on ClinicalTrials.gov ↗ ← All trials in the USA